Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Among authors: post fa. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; UK Collaborative HIV Cohort Study. Bansi L, et al. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):391-6. doi: 10.1097/QAI.0b013e3181ab73cc. J Acquir Immune Defic Syndr. 2009. PMID: 19553826
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Grant AD, et al. AIDS. 2009 Nov 27;23(18):2507-15. doi: 10.1097/QAD.0b013e3283320dfd. AIDS. 2009. PMID: 19770622
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC). Harrison L, et al. AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93. AIDS. 2010. PMID: 20588166
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.
UK Collaborative HIV Cohort (CHIC) Study Steering Committee; Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA. UK Collaborative HIV Cohort (CHIC) Study Steering Committee, et al. Eur J Neurol. 2011 Mar;18(3):527-34. doi: 10.1111/j.1468-1331.2010.03291.x. Epub 2010 Dec 15. Eur J Neurol. 2011. PMID: 21159073
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Prosperi MC, et al. J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. J Antimicrob Chemother. 2011. PMID: 21624929
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee. Barber TJ, et al. Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818. Antivir Ther. 2011. PMID: 21900712
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.
Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study. Kober C, et al. HIV Med. 2012 Jan;13(1):73-8. doi: 10.1111/j.1468-1293.2011.00956.x. Epub 2011 Nov 22. HIV Med. 2012. PMID: 22106827 Free article.
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees. Barber TJ, et al. J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17. J Antimicrob Chemother. 2012. PMID: 22258921
284 results